Eli Lilly and Company (NYSE:LLY) Shares Purchased by Latitude Advisors LLC

Latitude Advisors LLC grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 4.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,274 shares of the company’s stock after acquiring an additional 60 shares during the period. Latitude Advisors LLC’s holdings in Eli Lilly and Company were worth $743,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of LLY. Lipe & Dalton purchased a new position in Eli Lilly and Company during the 4th quarter valued at about $26,000. Thompson Investment Management Inc. purchased a new position in Eli Lilly and Company during the third quarter valued at approximately $27,000. Retirement Group LLC increased its stake in Eli Lilly and Company by 159.1% in the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock valued at $27,000 after buying an additional 35 shares during the period. Cornerstone Planning Group LLC acquired a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at about $33,000. Finally, Legacy Financial Group LLC bought a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at approximately $35,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the sale, the insider now owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Down 0.5 %

NYSE LLY traded down $4.03 on Wednesday, reaching $746.74. The company had a trading volume of 2,569,799 shares, compared to its average volume of 2,215,511. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a 52 week low of $367.35 and a 52 week high of $800.78. The stock has a market cap of $709.52 billion, a price-to-earnings ratio of 128.72, a PEG ratio of 1.64 and a beta of 0.34. The stock’s 50 day moving average is $763.51 and its 200-day moving average is $657.01.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business’s quarterly revenue was up 28.1% on a year-over-year basis. During the same period last year, the business earned $2.09 EPS. Equities analysts predict that Eli Lilly and Company will post 12.52 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Citigroup lifted their target price on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Truist Financial reaffirmed a “buy” rating and issued a $850.00 price target on shares of Eli Lilly and Company in a research report on Friday, March 22nd. The Goldman Sachs Group increased their price objective on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a report on Thursday, April 11th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $815.00 target price on shares of Eli Lilly and Company in a report on Monday. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.